• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

作者信息

Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros L J, Young K H, Rassidakis G Z

机构信息

Department of Oncology and Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden.

Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Leukemia. 2017 Jul;31(7):1633-1637. doi: 10.1038/leu.2017.103. Epub 2017 Mar 27.

DOI:10.1038/leu.2017.103
PMID:28344319
Abstract
摘要

相似文献

1
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.在ALK阴性间变性大细胞淋巴瘤中，程序性死亡受体配体1（PD-L1）通常表达，并受信号转导和转录激活因子3（STAT3）及原癌基因Myc转录调控。
Leukemia. 2017 Jul;31(7):1633-1637. doi: 10.1038/leu.2017.103. Epub 2017 Mar 27.
2
[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].ALK阴性间变性大细胞淋巴瘤中C-MYC和PD-L1的基因异常与蛋白表达
Zhonghua Bing Li Xue Za Zhi. 2021 Jun 8;50(6):598-603. doi: 10.3760/cma.j.cn112151-20201223-00953.
3
PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.PD-L1 表达与 ALK 阳性和 STAT3 激活相关，但与系统性间变大细胞淋巴瘤患者的预后无关。
Mod Pathol. 2020 Mar;33(3):324-333. doi: 10.1038/s41379-019-0336-3. Epub 2019 Aug 5.
4
A novel model of controlling PD-L1 expression in ALK anaplastic large cell lymphoma revealed by CRISPR screening.CRISPR 筛选揭示控制间变性大细胞淋巴瘤中 PD-L1 表达的新型模型。
Blood. 2019 Jul 11;134(2):171-185. doi: 10.1182/blood.2019001043. Epub 2019 May 31.
5
PD-L1 expression in anaplastic large cell lymphoma.间变性大细胞淋巴瘤中的程序性死亡受体配体1（PD-L1）表达
Mod Pathol. 2020 Jun;33(6):1232-1233. doi: 10.1038/s41379-019-0448-9. Epub 2020 Jan 2.
6
Reply to "PD-L1 expression in anaplastic large cell lymphoma".
Mod Pathol. 2020 Jun;33(6):1234-1235. doi: 10.1038/s41379-020-0522-3. Epub 2020 Mar 18.
7
Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.JUNB/CJUN对ALK+间变性大细胞淋巴瘤中AKT1基因表达的组成性调控：一种新的串扰机制。
Leukemia. 2015 Nov;29(11):2162-72. doi: 10.1038/leu.2015.127. Epub 2015 May 19.
8
Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.布雷菲德菌素 A 对间变性大细胞淋巴瘤和经典霍奇金淋巴瘤细胞系的作用存在差异。
Br J Haematol. 2015 Sep;170(6):837-46. doi: 10.1111/bjh.13508. Epub 2015 Jun 24.
9
Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.
Hematol Oncol. 2018 Feb;36(1):150-158. doi: 10.1002/hon.2455. Epub 2017 Jun 30.
10
Refractory case of ALK-negative anaplastic large-cell lymphoma with PAX-5 expression and T-cell receptor-γ gene rearrangement.
J Clin Exp Hematop. 2013;53(3):251-4. doi: 10.3960/jslrt.53.251.

引用本文的文献

1
Unraveling the role of STAT3 in Cancer Cachexia: pathogenic mechanisms and therapeutic opportunities.解析信号转导和转录激活因子3（STAT3）在癌症恶病质中的作用：致病机制与治疗机遇
Front Endocrinol (Lausanne). 2025 Jul 9;16:1608612. doi: 10.3389/fendo.2025.1608612. eCollection 2025.
2
PD-1/PD-L1 inhibitor treatment associated with cardiotoxicity regulated by macrophage polarization and SOCS3/JAK/STAT3 signaling pathway.PD-1/PD-L1抑制剂治疗与由巨噬细胞极化和SOCS3/JAK/STAT3信号通路调控的心脏毒性相关。
Cent Eur J Immunol. 2025;50(1):24-37. doi: 10.5114/ceji.2025.149377. Epub 2025 Apr 9.
3
Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer.

本文引用的文献

1
CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.CD274（程序性死亡配体1，PD-L1）/PDCD1（程序性死亡受体1，PD-1）在初发和转化型弥漫性大B细胞淋巴瘤中的表达
Br J Haematol. 2018 Mar;180(5):744-748. doi: 10.1111/bjh.14432. Epub 2016 Nov 23.
2
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.程序性死亡配体1（PD-L1）和程序性死亡配体2（PD-L2）基因改变可定义经典型霍奇金淋巴瘤并预测预后。
J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11.
3
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
信号素7A和程序性死亡受体配体1在乳腺退化和乳腺癌过程中协同驱动免疫抑制。
Cell Rep. 2025 May 27;44(5):115676. doi: 10.1016/j.celrep.2025.115676. Epub 2025 May 6.
4
Combination of Sodium Butyrate and Immunotherapy in Glioma: regulation of immunologically hot and cold tumors via gut microbiota and metabolites.丁酸钠与免疫疗法联合治疗胶质瘤：通过肠道微生物群和代谢产物调节免疫热肿瘤和免疫冷肿瘤
Front Immunol. 2025 Apr 14;16:1532528. doi: 10.3389/fimmu.2025.1532528. eCollection 2025.
5
Isoliquiritigenin attenuates tumor progression and PD-L1 expression by inhibiting the phosphorylation of STAT3 in melanoma.异甘草素通过抑制黑色素瘤中STAT3的磷酸化来减弱肿瘤进展和PD-L1表达。
Med Oncol. 2025 Mar 19;42(4):118. doi: 10.1007/s12032-025-02666-9.
6
Loss of MNX1 Sensitizes Tumors to Cytotoxic T Cells by Degradation of PD-L1 mRNA.MNX1缺失通过降解PD-L1 mRNA使肿瘤对细胞毒性T细胞敏感。
Adv Sci (Weinh). 2025 Mar;12(12):e2403077. doi: 10.1002/advs.202403077. Epub 2025 Feb 6.
7
NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma.在肝细胞癌中，NUAK1通过激活GSK-3β/β-连环蛋白信号通路，作为程序性死亡受体配体1（PD-L1）的新型调节因子发挥作用。
Mol Med. 2025 Feb 3;31(1):38. doi: 10.1186/s10020-025-01088-7.
8
Schisanhenol Inhibits the Proliferation of Hepatocellular Carcinoma Cells by Targeting Programmed Cell Death-ligand 1 the STAT3 Pathways.五味子醇通过靶向程序性细胞死亡配体1和STAT3信号通路抑制肝癌细胞增殖。
Anticancer Agents Med Chem. 2025;25(10):697-710. doi: 10.2174/0118715206349131241121091834.
9
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.含无菌α基序和HD结构域蛋白1（SAMHD1）在乳腺癌中的预后及预测意义
Int J Cancer. 2025 Apr 15;156(8):1621-1633. doi: 10.1002/ijc.35319. Epub 2024 Dec 27.
10
CD58 defines regulatory macrophages within the tumor microenvironment.CD58 在肿瘤微环境中定义了调节性巨噬细胞。
Commun Biol. 2024 Aug 21;7(1):1025. doi: 10.1038/s42003-024-06712-6.
评估程序性死亡受体1（PDL1）表达在霍奇金淋巴瘤和B细胞淋巴瘤中的诊断及预后价值。
Hum Pathol. 2016 Aug;54:17-24. doi: 10.1016/j.humpath.2016.03.005. Epub 2016 Apr 1.
4
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.弥漫性大 B 细胞淋巴瘤中 PD-L1 过表达的遗传基础。
Blood. 2016 Jun 16;127(24):3026-34. doi: 10.1182/blood-2015-12-686550. Epub 2016 Mar 30.
5
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
6
MYC regulates the antitumor immune response through CD47 and PD-L1.MYC 通过 CD47 和程序性死亡受体配体 1（PD-L1）调节抗肿瘤免疫反应。
Science. 2016 Apr 8;352(6282):227-31. doi: 10.1126/science.aac9935. Epub 2016 Mar 10.
7
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.程序性死亡配体1（PD-L1）的调控：促生存信号在癌症中的新作用
Ann Oncol. 2016 Mar;27(3):409-16. doi: 10.1093/annonc/mdv615. Epub 2015 Dec 17.
8
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.趋同突变和激酶融合导致间变性大细胞淋巴瘤中致癌性STAT3激活。
Cancer Cell. 2015 Apr 13;27(4):516-32. doi: 10.1016/j.ccell.2015.03.006.
9
The future of immune checkpoint therapy.免疫检查点疗法的未来。
Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
10
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤的 PD-1 阻断作用。
N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.